Literature DB >> 35421419

Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers.

Xin Chen1, Yi Liu1, Hejing Liu1, Zhi-Wei Wang2, Xueqiong Zhu3.   

Abstract

Human papillomavirus (HPV)-negative tumors distinguish from cancers associated with HPV infection. Due to its high rate of lymph node metastasis and difficulty in inchoate discover and diagnosis, the treatment efficacy of HPV-negative cancers is unsatisfactory. Epidemiological evidence suggests that HPV-negative tumor patients have a poor prognosis, and the mortality is higher than that of cancer patients caused by HPV infection. Evidence has demonstrated that noncoding RNAs (ncRNAs) play a crucial role in regulation of physiological and developmental processes. Therefore, dysregulated ncRNAs are involved in the occurrence of diversified diseases, including cancer. In cumulative studies, ncRNAs are concerned with pathogenetic mechanisms of HPV-negative tumors via regulating gene expression and signal transduction. It is important to decipher the functions of ncRNAs in HPV-negative cancers and identify the potential biomarkers, which will bring new treatment strategies for improving outcome of cancer therapy. In this review, we demonstrated the effects of ncRNAs via regulating the development and progression of HPV- negative tumors by directly or indirectly acting on target molecules, which provide a basis for future tumor targeted therapy by targeting ncRNAs for HPV-negative cancers.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinogenesis; HPV-negative cancer; LncRNAs; Noncoding RNA; miRNAs

Mesh:

Substances:

Year:  2022        PMID: 35421419     DOI: 10.1016/j.pharmthera.2022.108188

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   13.400


  6 in total

1.  CACNA1C-AS2 inhibits cell proliferation and suppresses cell migration and invasion via targeting FBXO45 and PI3K/AKT/mTOR pathways in glioma.

Authors:  Tong Cao; Yue Cui; Yingying Wang; Linhui Wu; Ke Yu; Kai Chen; Jun Xia; Yuyun Li; Zhiwei Peter Wang; Jia Ma
Journal:  Apoptosis       Date:  2022-08-29       Impact factor: 5.561

2.  LncRNA OIP5-AS1 Knockdown Targets miR-183-5p/GLUL Axis and Inhibits Cell Proliferation, Migration and Metastasis in Nasopharyngeal Carcinoma.

Authors:  Shuo Li; Mingxing Tang; Nan Zen; Junyi Liang; Xiao Xing; Danglin Huang; Fei Liu; Xiaomeng Zhang
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 3.  The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression.

Authors:  Lu Xia; Jingyun Chen; Min Huang; Jie Mei; Min Lin
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

4.  LncRNA SCAMP1 disrupts the balance between miR-26a-5p and ZEB2 to promote osteosarcoma cell viability and invasion.

Authors:  Rong Li; Zhen Chen; Yubo Zhou; Gulikezi Maimaitirexiati; Qi Yan; Yuting Li; Adilijiang Maimaitiyimin; Changhui Zhou; Jingqin Ren; Chengqing Liu; Abasi Mainike; Peng Zhou; Lu Ding
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

Review 5.  Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer.

Authors:  Linjiao Chen; Jie Wang; Qian Liu
Journal:  Front Cell Dev Biol       Date:  2022-08-29

6.  LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer.

Authors:  Zhengwei Song; Xiaoguang Wang; Fei Chen; Qiuli Chen; Wenjun Liu; Xiaodan Yang; Xun Zhu; Xiaorong Liu; Peter Wang
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.